Caris Molecular Intelligence® reports contain information about the molecular profile of a patient’s cancer tumour, which can guide decisions about treatment. The information contained in the report enables precision or personalised medicine, that is, matching of evidence-guided cancer treatment to the molecular profile of an individual patient’s tumour. The report is fully referenced to scientific evidence demonstrating the effectiveness of a range of therapies for treatment tumours with similar molecular biomarker profiles. It is sent to the patient’s doctor within 21 days of case activation.
What’s in the report?
The report is prepared by a team of doctors and scientists at the Caris Life Sciences® laboratory and summarises the most relevant treatment information, based on the tumour’s profile and biomarkers. Biomarkers are features of the tumour that are known to respond in particular ways to different treatments. Referencing information from the most important controlled scientific studies, the report details which chemotherapies, immunotherapies and targeted therapies are, and are not, likely to effectively treat that patient’s cancer. This integrated information helps the doctor to make an evidence-guided decision about the best treatment option.
The report includes information about the results of each biomarker test performed to profile the tumour, the genetic mutations that may be driving the tumour’s growth, and which are known to respond to different therapies. The information is compiled by scientists who are familiar with a large body of evidence about the effectiveness of different treatment – to date they have reviewed over 120,000 articles reporting the results of scientific studies. This information about the associations between particular mutations and treatments is important for understanding why particular therapies are likely or unlikely to be of benefit. The report also contains information about the results of clinical trials of new anti-cancer medicines that the patient may be able to participate in.
Who gets the report?
Precision Oncology sends the full report to the patient’s doctor, after which the doctor can discuss the information by email, with another doctor who works in the Caris lab. The doctor also has the option to discuss the results via teleconference. They may choose to do this because the Caris doctor is familiar with the rapidly changing scientific evidence about the associations between different cancer biomarkers and therapies.
Precision Oncology notifies the patient whose tumour has been profiled when the report has been sent to their doctor. However, as with all medical test results in Australia and New Zealand, they are not sent directly to the patient.